+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuropathic Pain Market and Forecast Analysis to 2026

  • ID: 4533528
  • Report
  • 293 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain. Neuropathic pain is not a single disease, but a syndrome caused by an array of different diseases and lesions, with common subtypes such as diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.

Market Snapshot
  • The opioid class is set to succeed anticonvulsants as market leader, as Lyrica faces generic competition in all markets.
  • Treatment of neuropathic pain has remained stagnant over recent years due to lack of innovation within the pain market.
  • The burden of neuropathic pain is difficult to estimate, but is likely high across all analyzed countries.
  • Lyrica continues to dominate neuropathic pain; however, revenues are set to fall dramatically following patent expiries.
  • Donaperminogene seltoplasmid is the only late-stage therapy to target the underlying cause of pain rather than symptoms.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: NEUROPATHIC PAIN (Published on 31 May 2018)
Overview
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Cymbalta
Product Profile: Gralise
Product Profile: Lidoderm
Product Profile: Lyrica
Product Profile: Nucynta Er
Product Profile (Late Stage): Cebranopadol
Product Profile (Late Stage): Donaperminogene Seltoplasmid
Product Profile (Late Stage): Mirogabalin
Product Profile (Late Stage): Raxatrigine

TREATMENT: NEUROPATHIC PAIN (Published on 13 March 2018)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Neuropathic Pain

EPIDEMIOLOGY: NEUROPATHIC PAIN (Published on 23 October 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography

MARKETED DRUGS: NEUROPATHIC PAIN (Published on 31 May 2018)
Overview
Product Overview
Product Profile: Cymbalta
Product Profile: Gralise
Product Profile: Lidoderm
Product Profile: Lyrica
Product Profile: Nucynta Er

PIPELINE: NEUROPATHIC PAIN (Published on 31 May 2018)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Cebranopadol
Product Profile (Late Stage): Donaperminogene Seltoplasmid
Product Profile (Late Stage): Mirogabalin
Product Profile (Late Stage): Raxatrigine

LIST OF FIGURES
Figure 1: Neuropathic pain – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for neuropathic pain
Figure 3: Neuropathic pain drug sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Drug sales across the US, Japan, and five major EU markets, by drug class, 2017–26
Figure 5: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype, 2017–26
Figure 6: Methodology flow for The authors neuropathic pain forecast
Figure 7: Price sources and calculations, by country
Figure 8: Cymbalta for neuropathic pain – SWOT analysis
Figure 9: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 10: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 11: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Gralise for neuropathic pain – SWOT analysis
Figure 13: The authors drug assessment summary of Gralise for neuropathic pain
Figure 14: The authors drug assessment summary of Gralise for neuropathic pain
Figure 15: Gralise sales for neuropathic pain in the US, 2017–26
Figure 16: Lidoderm for neuropathic pain – SWOT analysis
Figure 17: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 18: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 19: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Lyrica for neuropathic pain – SWOT analysis
Figure 21: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 22: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 23: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Nucynta ER for neuropathic pain – SWOT analysis
Figure 25: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 26: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 27: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017–26
Figure 28: Cebranopadol for neuropathic pain – SWOT analysis
Figure 29: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 30: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 31: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
Figure 32: Donaperminogene seltoplasmid for neuropathic pain – SWOT analysis
Figure 33: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 34: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 35: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017–26
Figure 36: Mirogabalin for neuropathic pain – SWOT analysis
Figure 37: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 38: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 39: Mirogabalin sales for neuropathic pain in Japan, 2017–26
Figure 40: Raxatrigine for neuropathic pain – SWOT analysis
Figure 41: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 42: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 43: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Figure 44: Surveyed respondents’ neuropathic pain patient caseload, by pain subtype
Figure 45: Surveyed respondents’ neuropathic pain patient caseload, by pain severity
Figure 46: 2010 EFNS recommendations for neuropathic pain
Figure 47: Neuropathic pain pharmacological treatment rates, by pain subtype
Figure 48: Top five therapies among first-line painful diabetic peripheral neuropathy patients, by country (%)
Figure 49: Top five therapies among second-line and beyond painful diabetic peripheral neuropathy patients, by country (%)
Figure 50: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 51: Top five therapies among second-line post-herpetic neuralgia patients, by country (%)
Figure 52: Top five therapies among first-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 53: Top five therapies among second-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 54: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 55: Top five therapies among second-line other chronic neuropathic pain patients, by country (%)
Figure 56: Key unmet needs for neuropathic pain
Figure 57: Trends in total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017–37
Figure 58: Cymbalta for neuropathic pain – SWOT analysis
Figure 59: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 60: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 61: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
Figure 62: Gralise for neuropathic pain – SWOT analysis
Figure 63: The authors drug assessment summary of Gralise for neuropathic pain
Figure 64: The authors drug assessment summary of Gralise for neuropathic pain
Figure 65: Gralise sales for neuropathic pain in the US, 2017–26
Figure 66: Lidoderm for neuropathic pain – SWOT analysis
Figure 67: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 68: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 69: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 70: Lyrica for neuropathic pain – SWOT analysis
Figure 71: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 72: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 73: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 74: Nucynta ER for neuropathic pain – SWOT analysis
Figure 75: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 76: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 77: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017–26
Figure 78: Cebranopadol for neuropathic pain – SWOT analysis
Figure 79: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 80: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 81: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
Figure 82: Donaperminogene seltoplasmid for neuropathic pain – SWOT analysis
Figure 83: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 84: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 85: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017–26
Figure 86: Mirogabalin for neuropathic pain – SWOT analysis
Figure 87: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 88: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 89: Mirogabalin sales for neuropathic pain in Japan, 2017–26
Figure 90: Raxatrigine for neuropathic pain – SWOT analysis
Figure 91: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 92: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 93: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26

LIST OF TABLES
Table 1: Neuropathic pain drug sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Drug sales across the US, Japan, and five major EU markets, by drug class ($m), 2017–26
Table 3: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype ($m), 2017–26
Table 4: Exchange rates used for calculating prices
Table 5: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
Table 6: Therapies included within neuropathic pain key opinion leader discussions
Table 7: Cymbalta drug profile
Table 8: Cymbalta Phase III data in neuropathic pain syndromes
Table 9: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Gralise drug profile
Table 11: Gralise Phase III data in post-herpetic neuralgia
Table 12: Gralise sales for neuropathic pain in the US ($m), 2017–26
Table 13: Lidoderm drug profile
Table 14: Lidoderm Phase III data in neuropathic pain syndromes
Table 15: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 16: Lyrica drug profile
Table 17: Lyrica Phase III data in diabetic neuropathy
Table 18: Lyrica Phase III data in post-herpetic neuralgia
Table 19: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 20: Nucynta ER drug profile
Table 21: Nucynta ER Phase III data in diabetic neuropathy
Table 22: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 23: Cebranopadol drug profile
Table 24: Cebranopadol Phase II data in neuropathic pain
Table 25: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
Table 26: Donaperminogene seltoplasmid drug profile
Table 27: Donaperminogene seltoplasmid Phase II data in neuropathic pain
Table 28: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
Table 29: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017–26
Table 30: Mirogabalin drug profile
Table 31: Mirogabalin Phase III data in neuropathic pain
Table 32: Mirogabalin Phase II data in neuropathic pain
Table 33: Mirogabalin sales for neuropathic pain in Japan ($m), 2017–26
Table 34: Raxatrigine drug profile
Table 35: Raxatrigine Phase II data in neuropathic pain
Table 36: Raxatrigine Phase III trials in neuropathic pain
Table 37: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 38: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
Table 39: Therapies discussed in the neuropathic pain key opinion leader primary research study, December 2017
Table 40: Common neuropathic pain conditions and their etiology
Table 41: Treatments available for neuropathic pain across the US, Japan, and five major EU markets
Table 42: International Association for the Study of Pain recommendations
Table 43: Treatment strategies for painful diabetic peripheral neuropathy patients, by country (%)
Table 44: Treatment strategies for post-herpetic neuralgia patients, by country (%)
Table 45: Treatment strategies for chemotherapy-induced peripheral neuropathy, by country (%)
Table 46: Treatment strategies for other chronic neuropathic pain patients, by country (%)
Table 47: Compliance rates of neuropathic pain patients across the US, Japan, and five major EU markets, by therapy type and country
Table 48: Relative importance of unmet needs in neuropathic pain treatment in the US, Japan, and five major EU markets, by country
Table 49: Sources used for painful peripheral diabetic neuropathy analysis in the US, Japan, and five major EU markets
Table 50: Segmentation of total neuropathic pain patients by pain type, by country
Table 51: Total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017–37
Table 52: Profiled key marketed drugs for neuropathic pain
Table 53: Cymbalta drug profile
Table 54: Cymbalta Phase III data in neuropathic pain syndromes
Table 55: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 56: Gralise drug profile
Table 57: Gralise Phase III data in post-herpetic neuralgia
Table 58: Gralise sales for neuropathic pain in the US ($m), 2017–26
Table 59: Lidoderm drug profile
Table 60: Lidoderm Phase III data in neuropathic pain syndromes
Table 61: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 62: Lyrica drug profile
Table 63: Lyrica Phase III data in diabetic neuropathy
Table 64: Lyrica Phase III data in post-herpetic neuralgia
Table 65: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 66: Nucynta ER drug profile
Table 67: Nucynta ER Phase III data in diabetic neuropathy
Table 68: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 69: Profiled pipeline products in development for neuropathic pain
Table 70: Cebranopadol drug profile
Table 71: Cebranopadol Phase II data in neuropathic pain
Table 72: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
Table 73: Donaperminogene seltoplasmid drug profile
Table 74: Donaperminogene seltoplasmid Phase II data in neuropathic pain
Table 75: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
Table 76: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017–26
Table 77: Mirogabalin drug profile
Table 78: Mirogabalin Phase III data in neuropathic pain
Table 79: Mirogabalin Phase II data in neuropathic pain
Table 80: Mirogabalin sales for neuropathic pain in Japan ($m), 2017–26
Table 81: Raxatrigine drug profile
Table 82: Raxatrigine Phase II data in neuropathic pain
Table 83: Raxatrigine Phase III trials in neuropathic pain
Table 84: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll